Drug Profile
RVT 3101
Alternative Names: PF 6480605; PF-06480605; RG-6631; RVT-3101Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Biological factors; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ulcerative colitis
- Phase II Crohn's disease
- Phase I Inflammatory bowel diseases
Most Recent Events
- 15 Feb 2024 Roche plans to file regulatory application for Crohn's disease in or after 2026 (Roche pipeline, February 2024)
- 15 Feb 2024 Roche plans to file regulatory application for Ulcerative colitis in or after 2026 (Roche pipeline, February 2024)
- 14 Dec 2023 Telavant has been acquired and merged into Roche